MedTrace Logo

Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

NCT03973879 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2020-02-11

No results posted yet for this study

Summary

This study evaluates the safety of PVSRIPO treatment in combination with Atezolizumab in patients with WHO grade IV malignant glioma. All patients will receive a single PVSRIPO infusion followed by atezolizumab infusions every three weeks for up to two years.

Conditions

  • Malignant Glioma

Interventions

BIOLOGICAL

PVSRIPO

Oncolytic polio/rhinovirus recombinant

DRUG

Atezolizumab

Antibody

Sponsors & Collaborators

  • Istari Oncology, Inc.

    collaborator INDUSTRY

  • Genentech, Inc.

    collaborator INDUSTRY

  • Darell Bigner

    lead OTHER

Principal Investigators

  • Darell D Bigner, MD, PhD · Istari Oncology, Inc.

  • Dina M Randazzo, DO · Duke University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-29
Primary Completion
2024-01-31
Completion
2024-01-31
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03973879 on ClinicalTrials.gov